YIH
SKYE icon

Y-Intercept (HK)’s Skye Bioscience SKYE Stock Holding History

Y-Intercept (HK)’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,046
Closed -$42K – 2136
2025
Q2 		$42K Buy
+10,046
New +$20.8K ﹤0.01% 1566

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Y-Intercept (HK)'s SKYE Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Skye Bioscience (SKYE) in Q3 2025, closing a stake of 10,046 shares — an estimated $42K sold.

Y-Intercept (HK) first reported a position in SKYE in Q2 2025 and held it in 1 quarter. The position peaked at $42K in Q2 2025. 58 funds tracked by Wall St. Rank hold SKYE as of Q3 2025.

  • Y-Intercept (HK) reported no remaining Skye Bioscience position as of Q3 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 10,046 Skye Bioscience shares in Q3 2025, an estimated $42K.
  • Y-Intercept (HK) first reported a position in Skye Bioscience in Q2 2025 and held it in 1 quarter.
  • Y-Intercept (HK)'s Skye Bioscience position peaked at $42K in Q2 2025.
  • 58 funds tracked by Wall St. Rank held Skye Bioscience as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.